Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;29(4):1285-92.
doi: 10.3892/or.2013.2279. Epub 2013 Feb 6.

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation

Laura Astolfi  1 , Sara Ghiselli, Valeria Guaran, Milvia Chicca, Edi Simoni, Elena Olivetto, Giorgio Lelli, Alessandro Martini
Affiliations

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation

Laura Astolfi et al. Oncol Rep. 2013 Apr.

Abstract

Cisplatin is the most common antineoplastic drug used for the therapy of solid tumours. To date, researchers have focused on the dosage to be administered for each specific tumour, mainly considering the local adverse effects. The aim of this study was to correlate the severity of the adverse effects with: i) the dosage of cisplatin; ii) the specific site of the tumour; iii) the association with other drugs; and iv) the symptoms. We analysed data from 123 patients with 11 different tumour classes undergoing therapy from 2007 to 2008 at St. Anna Hospital (Ferrara, Italy), using the Spearman non-parametric correlation index. Even though significant correlations were found among the variables, the overall results showed that the main factor influencing the severity of the adverse effects was the dosage of cisplatin administered.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlation between administered drug amounts and number of adverse effects. The daily and cumulative cisplatin amounts are expressed in mg/m2.
Figure 2
Figure 2
Correlations among side effects calculated by 1-r Pearson distance and plotted according to hierarchical union rank.
See this image and copyright information in PMC

References

    1. Blanchard EM. Cisplatin and solid tumours: still working, after all these years. J Solid Tumors. 2012;2:26–33.
    1. Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs. 2003;63:1565–1577. - PubMed
    1. Tewari KS, Monk BJ. Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005;7:419–434. - PubMed
    1. Armstrong DK, Bookman MA, McGuire W, Bristow RE, Schilder JM, Group GO. A phase I study of paclitaxel, topotecan, cisplatin and filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;105:667–671. - PMC - PubMed
    1. Ridwelski K, Gebauer T, Fahlke J, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol. 2001;12:47–51. - PubMed

Publication types